ArticlePloS one2014
Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Nidogen-1 could play a role in diabetic kidney disease development in type 2 diabetes: a genome-wide association meta-analysis.Human genomics · 2022Pooled it
- Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline.Kidney international · 2021Pooled it
- Natural History of Chronic Kidney Disease in Sickle Cell Disease.American journal of hematology · 2026Review
- Gene modification: Exploring the potential in treating kidney diseases.Pharmacological research · 2026Review
- Mechanisms of diabetic kidney disease and established and emerging treatments.Nature reviews. Endocrinology · 2026Review
- Loss of histone macroH2A1.1 causes kidney abnormalities secondary to a change in nutrient metabolization.Science advances · 2025Article
- Insights into the Novel Biomarkers Expressed in Diabetic Nephropathy: Potential Clinical Applications.Current pharmaceutical design · 2025Review
- Equitable community-based participatory research engagement with communities of color drives All of Us Wisconsin genomic research priorities.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- Epigenome-wide association study of diabetic chronic kidney disease progression in the Korean population: the KNOW-CKD study.Scientific reports · 2023Article
- Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.Breast cancer (Tokyo, Japan) · 2022Article
- Susceptibility ofFrontiers in medicine · 2021Article
- Impaired renal hemodynamics and glomerular hyperfiltration contribute to hypertension-induced renal injury.American journal of physiology. Renal physiology · 2020Article
- A Mutation inJournal of the American Society of Nephrology : JASN · 2020Article
- Genetic and Epigenetic Studies in Diabetic Kidney Disease.Frontiers in genetics · 2019Review
- Clinical and genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: a cross-sectional study.BMJ open · 2018Article
- Genetics of Obesity in Diverse Populations.Current diabetes reports · 2018Review
- Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease.Seminars in nephrology · 2018Review
- Microarray analysis reveals gene and microRNA signatures in diabetic kidney disease.Molecular medicine reports · 2018Article
- The Tubulointerstitial Pathophysiology of Progressive Kidney Disease.Advances in chronic kidney disease · 2017Review
- The (CTG)The Indian journal of medical research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Type 2 diabetes (T2D)-associated end-stage kidney disease (ESKD) is a complex disorder resulting from the combined influence of genetic and environmental factors. This study contains a comprehensive genetic analysis of putative nephropathy loci in 965 African American (AA) cases with T2D-ESKD and 1029 AA population-based controls extending prior findings. Analysis was based on 4,341 directly genotyped and imputed single nucleotide polymorphisms (SNPs) in 22 nephropathy candidate genes. After admixture adjustment and correction for multiple comparisons, 37 SNPs across eight loci were significantly associated (1.6E-05<P(emp)<0.049). Among these, variants in MYH9 were the most significant (1.6E-05<P(emp)<0.049), followed by additional chromosome 22 loci (APOL1, SFI1, and LIMK2). Nominal signals were observed in AGTR1, RPS12, CHN2 and CNDP1. Additional adjustment for APOL1 G1/G2 risk variants attenuated association at MYH9 (P(emp) = 0.00026-0.043) while marginally improving significance of other APOL1 SNPs (rs136161, rs713753, and rs767855; P(emp) = 0.0060-0.037); association at other loci was markedly reduced except for CHN2 (chimerin; rs17157914, P(emp)= 0.029). In addition, SNPs in other candidate loci (FRMD3 and TRPC6) trended toward association with T2D-ESKD (P(emp)<0.05). These results suggest that risk contributed by putative nephropathy genes is shared across populations of African and European ancestry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.